TheraRadar
← Back
Data updated: Jul 17, 2026

NATCO PHARMA LTD

Generics

NATCO PHARMA LTD is a generic drug manufacturer focused on Oncology, Neurology, Gastroenterology.

1987
Since
40
Drugs
-
Trials
1
New Drugs (2yr)
Modality:
1 Small Molecules

NATCO PHARMA LTD's Key Drugs

NATCO PHARMA LTD's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

NATCO PHARMA LTD's Therapeutic Areas

NATCO PHARMA LTD's approved drugs and pipeline span 5 therapeutic areas, led by Oncology and Neurology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Oncology 32%
3 drugs Phase 2: 1
Neurology 29%
3 drugs
Gastroenterology 19%
2 drugs
Immunology 10%
1 drugs
Infectious Disease 10%
1 drugs

NATCO PHARMA LTD Pipeline Snapshot

NATCO PHARMA LTD has 1 active clinical program from ClinicalTrials.gov — 0 Phase 3, 1 Phase 2 and 0 Phase 1.

0
Phase 3
1
Phase 2
0
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Oncology pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling